SUBSCRIBE
SUBSCRIBE

Alkermes

NEWS
Biotech Beach
The Day In Review: Dyax Corp. Jumps On Positive Data
April 13, 2007
 · 
1 min read
Biotech Beach
The Day In Review: Novartis Pharmaceuticals Corporation Gets Approval For Hypertensive Drug Tekturna
March 6, 2007
 · 
1 min read
BioForest
The Day In Review: Seattle Genetics, Inc. Sells Cancer Drug To Genentech, Inc.
January 8, 2007
 · 
1 min read
Biotech Bay
Alkermes More Than A Drug Delivery Company
July 17, 2006
 · 
1 min read
Biotech Beach
The Day In Review: Alkermes And Cephalon, Inc. Alcohol Drug Gets Approvable Letter
December 29, 2005
 · 
1 min read
Alkermes’ Alcohol Alchemy
October 19, 2005
 · 
1 min read
Drug Development
The Day In Review: Biotech Gains A Substantial 1+%; A Wealth of Positive News Helps Sector Move Higher
October 19, 2005
 · 
1 min read
Policy
U.S. Study Backs Injectable Drug For Alcoholism
October 19, 2005
 · 
1 min read
Bated Breath For Inhaled Insulin
October 19, 2005
 · 
1 min read
Load More
JOBS
IN THE PRESS
Press Releases
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
June 18, 2026
 · 
11 min read
Press Releases
Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe
June 15, 2026
 · 
8 min read
Press Releases
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research
June 4, 2026
 · 
19 min read
Press Releases
Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
June 4, 2026
 · 
1 min read
Press Releases
Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting
May 26, 2026
 · 
19 min read
Press Releases
Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences
May 21, 2026
 · 
19 min read
Press Releases
Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia
May 12, 2026
 · 
18 min read
Press Releases
Alkermes plc Reports First Quarter 2026 Financial Results
May 5, 2026
 · 
1 min read
Press Releases
Alkermes to Report First Quarter Financial Results on May 5, 2026
April 22, 2026
 · 
1 min read
Press Releases
Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting
April 17, 2026
 · 
10 min read
Load More